AdimmuneTPE:4142 58 Return-on-Tangible-Equity is 18.34% as of Dec. 2025. GuruFocus rates TPE:4142 with a GF Score™ of 58/100 and a GF Value™ of NT$25.61 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,196 Biotechnology companies, Adimmune ranks better than 73.83% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Adimmune's annualized net income for the quarter that ended in Dec. 2025 was NT$882 Mil. Adimmune's average shareholder tangible equity for the quarter that ended in Dec. 2025 was NT$4,807 Mil. Therefore, Adimmune's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 18.34%.
The historical rank and industry rank for Adimmune's Return-on-Tangible-Equity or its related term are showing as below:
TPE:4142'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -36.5 Med: -7.97 Max: 25.65
Current: -4.9
During the past 13 years, Adimmune's highest Return-on-Tangible-Equity was 25.65%. The lowest was -36.50%. And the median was -7.97%.
TPE:4142's Return-on-Tangible-Equity is ranked better than 73.83% of 1196
companies
in the Biotechnology industry
Industry Median: -42.19
vs TPE:4142: -4.90
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Adimmune Return-on-Tangible-Equity Related Terms
Adimmune Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Adimmune's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4142 vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Adimmune's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adimmune Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adimmune's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Adimmune's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 18.34% mean?
Adimmune (TPE:4142) has a Return-on-Tangible-Equity of 18.34% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Adimmune and its competitors. According to the industry distribution chart, Adimmune ranks #313 out of 1196 companies in the Biotechnology industry, placing it in the top 26.2%.
Is Adimmune's Return-on-Tangible-Equity too high?
Adimmune's current Return-on-Tangible-Equity is 18.34%. Based on the distribution chart, Adimmune ranks #313 out of 1196 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Adimmune has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Adimmune's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Adimmune ranks #313 out of 1196 companies for Return-on-Tangible-Equity. This puts Adimmune in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Adimmune and its competitors. Adimmune's current Return-on-Tangible-Equity is 18.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adimmune stock overvalued right now?
Based on GuruFocus' analysis, Adimmune (TPE:4142) is currently considered Possible Value Trap. The stock's GF Value™ is NT$25.61, compared to a current price of NT$17.65 — trading 31.1% below its estimated fair value. The current Return-on-Tangible-Equity is 18.34%. Adimmune's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Adimmune (TPE:4142), the current Return-on-Tangible-Equity is 18.34% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adimmune (TPE:4142) Overvalued in 2026?
Based on GuruFocus' analysis, Adimmune stock appears to be undervalued.
The current stock price of NT$17.65 is trading 31.1% below its estimated GF Value™ of NT$25.61.
GuruFocus considers Adimmune to be Possible Value Trap.
Key valuation signals for TPE:4142:
Return-on-Tangible-Equity: 18.34%
GF Value™: NT$25.61 vs. price of NT$17.65 (31.1% below fair value)
No single metric tells the full story. See the TPE:4142 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adimmune Corp is engaged in the research and development, processing, manufacturing, and trading of serum, vaccines, testing reagents, biologicals, and other bacterial fluids, as well as western medicines, animal medicines, chemicals, and feed additives. Its segments are separated by business as Adimmune Corporation, which generates maximum revenue and is engaged in the manufacturing of influenza vaccines with EU GMP and US FDA certificates in Taiwan. Its products include Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine, Influenza A (H1N1) Virus Monovalent Vaccine, and others, and Enimmune Corporation. The Group's revenue is mainly from the manufacturing and trading of vaccines, modern medicine products and testing reagents, as well as entrusted packing of vaccines.
58GF Score
Get the complete analysis for TPE:4142
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4142 has been successfully added to your 
